Ankur Dhingra is recorded as Head of Investor Relations at Agilent Technologies, Inc. (A) and CFO at Illumina, Inc. (ILMN). The newest filing on record that lists Ankur Dhingra as CFO at Illumina, Inc. (ILMN) is dated April 9, 2026. Ankur Dhingra was last confirmed as CFO at CareDx, Inc. (CDNA) in a filing dated April 28, 2023. Earlier roles on record: CFO at CareDx, Inc. (CDNA) until May 25, 2022 and CFO at Summit Therapeutics Inc. (SMMT) until April 2, 2024. Illumina, Inc. reported in an 8-K filed April 9, 2024 that Ankur Dhingra was appointed Chief Financial Officer, effective April 15, 2024. Summit Therapeutics Inc. reported in an 8-K filed April 3, 2024 that Ankur Dhingra resigned as Chief Financial Officer, effective April 2, 2024. The proxy statement of Illumina, Inc. reports total compensation of $4,078,071 for Ankur Dhingra in fiscal 2025, including a base salary of $650,000. Disclosed compensation is on record for 5 fiscal years. Ankur Dhingra has spoken on 22 earnings calls across 4 companies, most recently for Illumina, Inc. on April 30, 2026. Those appearances were for Illumina, Inc. (ILMN), CareDx, Inc. (CDNA), Summit Therapeutics Inc. (SMMT) and Agilent Technologies, Inc. (A). Illumina, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Agilent Technologies, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other companies whose calls Ankur Dhingra spoke on are classified in the Healthcare sector. Other leadership on record at Illumina, Inc. includes Jay T. Flatley (Chairman), John W. Thompson (Chairman), Scott Gottlieb (Chairman and Board Member) and 7 others.
“Ankur Dhingra has been appointed Chief Financial Officer of the Company, effective April 15, 2024 (the "Appointment Date").”
Illumina, Inc. Form 8-K, filed April 9, 2024
· Read the filing
“On April 2, 2024, Ankur Dhingra, the principal financial officer and principal accounting officer of Summit Therapeutics Inc. (the “Company”), resigned as Chief Financial Officer of the Company.”
Summit Therapeutics Inc. Form 8-K, filed April 3, 2024
· Read the filing
Ankur Dhingra on recent calls
“I will walk through our first quarter financial results, provide additional color on revenue, expenses, earnings, and our balance sheet and capital deployment, and then discuss our updated outlook.”
“So, and Doug, your premise that next year, excluding SomaLogic, that the exit rate operating margin for 2026 is higher than the average, that's usually our cyclicality in the business.”
“I will give you an overview of our third quarter financial results, provide more color about revenue, expenses, earnings and capital deployment and then speak about our outlook going forward.”
“I will give you an overview of our second quarter financial results, provide more color about revenue, expenses, earnings and developments on our balance sheet and capital deployment and then speak about our outlook going forward.”
“I will give you an overview of first quarter financial results and provide more color about our revenue, expenses, earnings, and developments on our balance sheet, and then speak about our outlook going forward.”
